TylenolRecall
J&J Apologizes for Kids Medicine Issues, Phantom Recalls
In testimony before Congress Thursday, Johnson & Johnson's CEO apologized for the problems that have beset his company, including the quality issues with its children's medicines and the "phantom recall" of a batch of Motrin. He also said new batches of its children's medicines should start shipping next week.
Johnson & Johnson Earnings Up, but Recalls Cut Guidance
Johnson & Johnson's earnings for the second quarter of 2010 rose 5.4% to $3.4 billion, or $1.23 per share, from $3.2 billion or $1.15 per share, the company announced Tuesday morning. Adjusted earnings, which exclude litigation costs, were $1.21 per share.
No New Children's Tylenol on Shelves This Year
Johnson & Johnson said Thursday that the Fort Washington, Pa., facility where it produced children's medications will probably stay shut down for the rest of 2010, meaning that no new supplies of those medicines will be available this year.
These Days, a Good Reputation Is Everything
Some companies don't realize how important their image is until it's gone. A new survey of corporate directors shows that reputation may account for 70% of a company's value.
J&J Recall Hearing: Contradictions and Cover-Ups
At Congress' hearings on Johnson & Johnson's huge drug recall, the company's statements were contradicted by the FDA, and details of its Motrin "phantom recall" were revealed.
J&J's Motrin Recall Cover-Up Revealed
Ahead of a Congressional hearing over Johnson & Johnson's big drug recall, internal documents were revealed that showed the drugmaker trying to conduct a stealth recall of Motrin in 2008. That's just one of the series of problems discovered at J&J.
